Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

ROIV

Roivant Sciences Ltd

Feb 12 • 04:00PM ET

26.75

-0.05 -0.19 %

Healthcare • Biotechnology • United Kingdom • NASD

Peers: VRTX REGN BIIB BMRN ALNY CRSP INCY NBIX IONS EDIT

| Held by: IJH VTI VB XBI VBK VXF MDY IBB SPMD DFAS

Index	-	P/E	-	EPS (ttm)	-1.17	Insider Own	37.10%	Shs Outstand	709.69M	Perf Week	26.54%
Market Cap	19.14B	Forward P/E	-	EPS next Y	-1.20	Insider Trans	-8.25%	Shs Float	450.16M	Perf Month	14.12%
Enterprise Value	15.43B	PEG	-	EPS next Q	-0.30	Inst Own	69.86%	Short Float	5.17%	Perf Quarter	27.99%
Income	-809.24M	P/S	1438.39	EPS this Y	-352.84%	Inst Trans	7.75%	Short Ratio	3.21	Perf Half Y	123.66%
Sales	13.31M	P/B	4.45	EPS next Y	-10.51%	ROA	-14.69%	Short Interest	23.29M	Perf YTD	23.27%
Book/sh	6.02	P/C	4.22	EPS next 5Y	-	ROE	-17.11%	52W High	27.94 -4.26%	Perf Year	156.23%
Cash/sh	6.33	P/FCF	-	EPS past 3/5Y	42.73% -99.51%	ROIC	-18.53%	52W Low	8.73 206.41%	Perf 3Y	235.63%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-19.30% -	Gross Margin	60.46%	Volatility	5.55% 3.75%	Perf 5Y	156.23%
Dividend TTM	-	EV/Sales	1159.00	EPS Y/Y TTM	-751.06%	Oper. Margin	-9130.53%	ATR (14)	1.09	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	30.66	Sales Y/Y TTM	-86.36%	Profit Margin	-6079.94%	RSI (14)	69.44	Recom	1.36
Dividend Gr. 3/5Y	- -	Current Ratio	30.66	EPS Q/Q	-262.80%	SMA20	13.87%	Beta	1.18	Target Price	32.70
Payout	-	Debt/Eq	0.03	Sales Q/Q	-77.83%	SMA50	18.94%	Rel Volume	0.97	Prev Close	26.80
Employees	750	LT Debt/Eq	0.02	Earnings	Feb 06 BMO	SMA200	66.93%	Avg Volume	7.25M	Price	26.75
IPO	Dec 08, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	43.41% -60.65%	Trades		Volume	7,078,561	Change	-0.19%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-02-25	Initiated	Citigroup	Buy	$16
Jul-10-25	Resumed	Goldman	Buy	$19
Feb-15-24	Initiated	Wolfe Research	Outperform	$17
Jan-05-24	Initiated	Piper Sandler	Overweight	$20
Dec-12-23	Initiated	Deutsche Bank	Buy	$14
Oct-17-23	Initiated	Guggenheim	Buy	$17
Jun-08-23	Initiated	BofA Securities	Neutral	$10.50
Oct-27-22	Initiated	JP Morgan	Overweight	$7
May-23-22	Initiated	SVB Leerink	Outperform	$6
Apr-29-22	Initiated	Cantor Fitzgerald	Overweight	$15
Dec-15-21	Initiated	Goldman	Buy	$15
Nov-08-21	Initiated	H.C. Wainwright	Buy	$14
Oct-28-21	Initiated	Citigroup	Buy	$11
Oct-26-21	Initiated	Truist	Buy	$15
Oct-26-21	Initiated	Jefferies	Buy	$10
Oct-26-21	Initiated	Cowen	Outperform

Show Previous Ratings

Feb-10-26 06:41AM	TD Cowen Remains Bullish on Roivant Sciences Ltd. (ROIV) - Here's Why (Insider Monkey)
Feb-08-26 08:39AM	Lumentum, Woodward, And Teradyne Are Among the Top 10 Large-Cap Gainers Last Week (Feb. 2-Feb. 6): Are the Others in Your Portfolio? (Benzinga)
Feb-07-26 06:38AM	Roivant Sciences (ROIV) Soars 19.4% as Pipeline Drugs Progress (Insider Monkey)
Feb-06-26 02:05PM	Roivant Stock Soars On Experimental Skin Drug Delivering 100% Response - Why It Matters (Benzinga) +22.14%
02:00PM	Roivant Sciences Ltd (ROIV) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial ... (GuruFocus.com)
01:25PM	Loading…
01:25PM	Tech Bounces As Software Sell-Off Eases, Dow Jones Hits Records: What's Moving Markets Friday? (Benzinga)
10:10AM	Roivant Sciences Q3 Earnings Call Highlights (MarketBeat)
10:03AM	Roivant Sciences Catapults On A 'Dream Scenario' For Its Blockbuster Hopeful (Investor's Business Daily)
08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025 (GlobeNewswire)
07:00AM	Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) (GlobeNewswire)
Feb-01-26 07:47AM	January jobs data, Alphabet and Amazon earnings, more Warsh fallout: What to watch this week (Yahoo Finance)
Jan-23-26 04:15PM	Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 (GlobeNewswire)
Jan-20-26 10:31AM	Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report (Benzinga)
Jan-02-26 10:50AM	Leerink Raises Price Target as Roivant (ROIV) Accelerates Drug Development Pipeline (Insider Monkey)
08:10AM	Loading…
Dec-22-25 08:10AM	Insider Action: Multimillion-dollar sell-offs across major U.S. companies (CNBC TV)
Dec-11-25 07:30AM	Roivant Highlights Continued Pipeline Progress and Outlook for Company's Next Phase of Growth at 2025 Investor Day (GlobeNewswire) +5.43%
Dec-10-25 02:00AM	A Roivant spinout bets on AI-designed drugs for immune conditions (BioPharma Dive)
02:00AM	A former Roivant spinout bets on AI-designed drugs for immune conditions (BioPharma Dive)
Nov-10-25 02:01PM	Roivant Sciences Ltd (ROIV) Q2 2025 Earnings Call Highlights: Strong Financial Position and ... (GuruFocus.com)
08:25AM	Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update (GlobeNewswire)
Nov-06-25 09:15AM	Urogen Pharma (URGN) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-05-25 09:10AM	LENZ Therapeutics, Inc. (LENZ) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Nov-04-25 07:30AM	Do You Believe in the Growth Prospects of Roivant Sciences Ltd. (ROIV)? (Insider Monkey)
Oct-27-25 04:10PM	Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 (GlobeNewswire)
Oct-21-25 05:52AM	Wall Street Has a Mixed Opinion on Roivant Sciences Ltd (ROIV) (Insider Monkey)
Oct-04-25 04:54PM	Roivant's Brepocitinib Phase 3 Dermatomyositis Trial Hits Primary and All Key Secondary Endpoints (Insider Monkey)
Sep-29-25 08:01PM	Vivek Ramaswamy's Bitcoin Play Just Got Bigger: This $1.3B Deal Could Signal Corporate Crypto's Next Phase (Benzinga)
Sep-23-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Roivant Sciences Ltd. (ROIV) is a Great Choice (Zacks)
10:21AM	Loading…
Sep-22-25 10:21AM	Ramaswamy-backed Strive to buy Semler in $1.3 billion deal all stock deal, boosting Bitcoin holdings (Reuters)
Sep-18-25 10:47AM	Roivant Sciences (ROIV) Hits New All-Time High as Drug Candidate Clinical Trial Posts Impressive Results (Insider Monkey)
10:34AM	Montes Archimedes Acquisition (ROIV) Surges 7.8%: Is This an Indication of Further Gains? (Zacks)
Sep-17-25 04:11PM	Roivant Flirts With A Profit-Taking Zone, Stoked By Promise In Autoimmune Disease (Investor's Business Daily) +7.76%
12:49PM	Why Roivant Sciences Stock Is Soaring Today (Motley Fool)
07:00AM	Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM) (GlobeNewswire)
Sep-14-25 04:00AM	Vivek Ramaswamy Sells $22.7 Million of Roivant Sciences Stock (Barrons.com)
Sep-11-25 04:30PM	Roivant Named on Fortune Media and Great Place To Work's 2025 Best Workplaces in BioPharma List (GlobeNewswire)
11:11AM	Roivant Sciences Ltd. (ROIV) Wins Orphan Drug Status in Japan for Mosliciguat (Insider Monkey)
Sep-03-25 01:01PM	Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients (GlobeNewswire)
Aug-28-25 11:49PM	Roivant Sciences (ROIV) Announces Q1 2025 Business Update (Insider Monkey)
Aug-12-25 06:42PM	Why Roivant Sciences Stock Bounced Back on Tuesday (Motley Fool)
03:02AM	Roivant Sciences Ltd (ROIV) Q1 2025 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com)
Aug-11-25 04:58PM	Why Roivant Sciences Stock Was Slipping on Monday (Motley Fool)
08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update (GlobeNewswire)
Aug-08-25 09:17AM	What To Expect From Roivant Sciences Ltd (ROIV) Q1 2026 Earnings (GuruFocus.com)
Aug-07-25 06:15PM	Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Aug-05-25 08:10AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Jul-28-25 04:05PM	Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025 (GlobeNewswire)
Jul-24-25 11:47PM	Goldman Sachs Resumes Roivant Sciences (ROIV) Coverage with 'Buy' Rating (Insider Monkey)
Jul-11-25 06:20AM	Should Invesco S&P MidCap 400 GARP ETF (GRPM) Be on Your Investing Radar? (Zacks)
Jun-24-25 12:45PM	Roivant Sciences Subsidiary Pulmovant Publishes Positive Phase 1 Data for Inhaled PH Treatment Mosliciguat (Insider Monkey)
Jun-16-25 07:00AM	Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics (GlobeNewswire)
Jun-09-25 04:05PM	Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis (GlobeNewswire)
May-29-25 08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +6.40%
07:00AM	Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update (GlobeNewswire)
May-28-25 02:17PM	H.C. Wainwright Keeps Buy Rating on Roivant Sciences (ROIV) Stock (Insider Monkey)
09:15AM	What To Expect From Roivant Sciences Ltd (ROIV) Q4 2025 Earnings (GuruFocus.com)
May-15-25 05:15PM	Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:10PM	Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025 (GlobeNewswire)
May-14-25 05:40PM	Codexis (CDXS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-13-25 05:10PM	Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-08-25 07:45AM	Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-06-25 06:20AM	Should Invesco S&P MidCap 400 Pure Growth ETF (RFG) Be on Your Investing Radar? (Zacks)
May-02-25 10:37AM	Roivant Sciences Ltd. (ROIV): Among David Einhorn's Stock Picks with Huge Upside Potential (Insider Monkey)
Apr-29-25 11:35AM	Roivant Sciences Ltd. (ROIV): Among Billionaire Andreas Halvorsen's Stock Picks With Huge Upside Potential (Insider Monkey)
Apr-23-25 12:13PM	Roivant Sciences: Primed For Growth With A De-Risked Pipeline (Seeking Alpha)
Apr-21-25 04:08PM	Immunovant Dives On Its C-Suite Sweep, Narrowed Plans For Leading Drug (Investor's Business Daily)
10:18AM	Immunovant Crumbles After Roivant Sweeps Out Its C-Suite, Unveils Strategic Shift (Investor's Business Daily)
07:00AM	Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjogren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 (GlobeNewswire)
07:00AM	Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sj gren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 (GlobeNewswire)
Apr-14-25 06:20AM	Is Invesco S&P MidCap 400 Pure Growth ETF (RFG) a Strong ETF Right Now? (Zacks)
Apr-11-25 03:07PM	Is Roivant Sciences Ltd. (ROIV) the Top Healthcare Stock to Buy According to Billionaire David Einhorn? (Insider Monkey)
10:04AM	Certara (CERT) Soars 8.0%: Is Further Upside Left in the Stock? (Zacks)
Apr-10-25 05:08PM	Roivant Sciences Ltd. (ROIV): Among the Best Low Priced Growth Stocks to Invest In (Insider Monkey)
Mar-31-25 04:03PM	Impax Small Cap Fund Q4 2024 Commentary (Seeking Alpha)
Mar-29-25 04:00PM	Is Roivant Sciences (ROIV) the Best Mid Cap Biotech Stock to Buy? (Insider Monkey)
Mar-25-25 02:12PM	Is Roivant Sciences Ltd. (NASDAQ:ROIV) One of The Best Stocks to Buy According to Billionaire David Einhorn? (InsiderMonkey)
Mar-19-25 04:04PM	Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose. (Investor's Business Daily)
09:26AM	Roivant, Immunovant Succeed In Phase 3. But There's A Twist And Shares Tumbled. (Investor's Business Daily)
07:45AM	Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies (GlobeNewswire)
Mar-18-25 04:32PM	Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs (GlobeNewswire)
Mar-03-25 09:15AM	Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna (GlobeNewswire) -5.31%
Feb-25-25 08:00AM	Early Warning Report Issued Pursuant to National Instrument 62 103: Roivant announces Resignation and Replacement of Arbutus Board (GlobeNewswire)
Feb-12-25 10:00AM	Roivant Sciences price target lowered to $12 from $13 at BofA (TipRanks)
Feb-10-25 07:00AM	Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update (GlobeNewswire)
Feb-07-25 07:06AM	What To Expect From Roivant Sciences Ltd (ROIV) Q3 2025 Earnings (GuruFocus.com)
Feb-03-25 07:00AM	Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care (GlobeNewswire)
Jan-29-25 04:05PM	Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025 (GlobeNewswire)
Jan-15-25 08:49PM	Vivek Ramaswamy Open to Replacing JD Vance in Senateif Offered (The Wall Street Journal)
Jan-12-25 09:40AM	Is Roivant Sciences (ROIV) the Best Medical Stock to Buy Under $20? (Insider Monkey)
Jan-02-25 03:28AM	Why Roivant Sciences Ltd. (ROIV) Is Skyrocketing (Insider Monkey)
Dec-03-24 07:00AM	Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis (GlobeNewswire)
07:00AM	Kinevant Sciences Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis (GlobeNewswire)
Nov-15-24 05:01PM	Vivek Ramaswamy's Net Worth Is 9 Figures See How the DOGE Co-Lead Made His Millions (Investopedia)
Nov-12-24 07:00AM	Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update (GlobeNewswire)
Nov-11-24 07:04AM	Roivant Sciences Ltd (ROIV) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-29-24 04:35PM	Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024 (GlobeNewswire)
Oct-28-24 09:25AM	Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA (tapinarof) Cream, 1% (GlobeNewswire)

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sukhatme Mayukh	President & CIO	Feb 09 '26	Option Exercise	12.68	651,558	8,261,755	19,488,105	Feb 11 05:53 PM
Sukhatme Mayukh	President & CIO	Feb 09 '26	Sale	26.47	339,441	8,985,003	19,148,664	Feb 11 05:53 PM
Sukhatme Mayukh	Officer	Feb 09 '26	Proposed Sale	26.47	339,441	8,985,276		Feb 09 04:13 PM
Venker Eric	President & Immunovant CEO	Jan 12 '26	Option Exercise	3.85	200,000	770,000	1,854,597	Jan 14 09:00 PM
Venker Eric	President & Immunovant CEO	Jan 12 '26	Sale	21.92	200,000	4,384,000	1,654,597	Jan 14 09:00 PM
Venker Eric	Officer	Jan 12 '26	Proposed Sale	21.92	200,000	4,383,694		Jan 12 04:04 PM
Sukhatme Mayukh	President & CIO	Dec 31 '25	Option Exercise	12.68	2,449,877	31,064,440	21,286,424	Dec 31 09:00 PM
Sukhatme Mayukh	President & CIO	Dec 29 '25	Option Exercise	12.68	748,358	9,489,179	19,584,905	Dec 31 09:00 PM
Sukhatme Mayukh	President & CIO	Dec 31 '25	Sale	21.71	1,018,995	22,122,381	20,267,429	Dec 31 09:00 PM
Sukhatme Mayukh	President & CIO	Dec 29 '25	Sale	21.74	311,873	6,780,119	19,273,032	Dec 31 09:00 PM
Sukhatme Mayukh	Officer	Dec 31 '25	Proposed Sale	21.71	1,018,995	22,119,828		Dec 31 04:30 PM
Pulik Richard	CFO	Dec 23 '25	Option Exercise	3.85	260,000	1,001,000	646,144	Dec 29 09:00 PM
Pulik Richard	CFO	Dec 23 '25	Sale	22.43	406,731	9,122,307	239,413	Dec 29 09:00 PM
Venker Eric	President & Immunovant CEO	Dec 23 '25	Option Exercise	3.85	313,841	1,208,288	1,811,749	Dec 29 09:00 PM
Venker Eric	President & Immunovant CEO	Dec 24 '25	Option Exercise	3.85	117,848	453,715	1,729,597	Dec 29 09:00 PM
Venker Eric	President & Immunovant CEO	Dec 23 '25	Sale	22.45	200,000	4,490,000	1,611,749	Dec 29 09:00 PM
Venker Eric	President & Immunovant CEO	Dec 24 '25	Sale	22.53	75,000	1,689,750	1,654,597	Dec 29 09:00 PM
Sukhatme Mayukh	Officer	Dec 29 '25	Proposed Sale	21.74	311,873	6,781,263		Dec 29 04:31 PM
ERIC VENKER	Officer	Dec 24 '25	Proposed Sale	22.53	75,000	1,689,562		Dec 29 09:36 AM
FRANK M TORTI	Officer	Dec 24 '25	Proposed Sale	22.47	64,891	1,458,373		Dec 29 09:05 AM
RICHARD PULIK	Officer	Dec 23 '25	Proposed Sale	22.45	260,000	5,835,726		Dec 23 04:19 PM
RICHARD PULIK TRUST	Officer	Dec 23 '25	Proposed Sale	22.39	146,731	3,285,755		Dec 23 04:07 PM
ERIC VENKER	Officer	Dec 23 '25	Proposed Sale	22.45	200,000	4,490,540		Dec 23 04:04 PM
Sukhatme Mayukh	President & CIO	Dec 17 '25	Option Exercise	12.68	59,513	754,625	18,896,060	Dec 19 09:04 PM
Sukhatme Mayukh	President & CIO	Dec 17 '25	Sale	23.09	26,831	619,528	18,869,229	Dec 19 09:04 PM
Gold Daniel Allen	Director	Dec 16 '25	Sale	23.04	917,282	21,129,619	17,130,445	Dec 18 07:54 PM
Gold Daniel Allen	Director	Dec 17 '25	Sale	23.07	777,332	17,935,595	16,353,113	Dec 18 07:54 PM
MANCHESTER KEITH S	Director	Dec 16 '25	Sale	23.04	917,282	21,129,619	17,130,445	Dec 18 07:52 PM
MANCHESTER KEITH S	Director	Dec 17 '25	Sale	23.07	777,332	17,935,595	16,353,113	Dec 18 07:52 PM
QVT Financial LP	Director by Deputization	Dec 16 '25	Sale	23.04	917,282	21,129,619	17,130,445	Dec 18 07:41 PM
QVT Financial LP	Director by Deputization	Dec 17 '25	Sale	23.07	777,332	17,935,595	16,353,113	Dec 18 07:41 PM
Gline Matthew	CEO	Dec 15 '25	Option Exercise	12.16	3,870,659	47,062,049	19,559,933	Dec 17 09:00 PM
Gline Matthew	CEO	Dec 15 '25	Sale	21.68	1,740,000	37,723,200	17,290,820	Dec 17 09:00 PM
Sukhatme Mayukh	Officer	Dec 17 '25	Proposed Sale	23.09	26,831	619,488		Dec 17 05:09 PM
Ramaswamy Vivek	10% Owner	Dec 12 '25	Option Exercise	12.68	4,672,724	59,250,140	38,326,479	Dec 15 09:34 PM
Ramaswamy Vivek	10% Owner	Dec 11 '25	Option Exercise	12.68	1,869,691	23,707,682	35,523,447	Dec 15 09:34 PM
Ramaswamy Vivek	10% Owner	Dec 15 '25	Option Exercise	12.68	832,453	10,555,504	34,486,208	Dec 15 09:34 PM
Ramaswamy Vivek	10% Owner	Dec 12 '25	Sale	21.96	1,975,858	43,389,842	36,350,621	Dec 15 09:34 PM
Ramaswamy Vivek	10% Owner	Dec 11 '25	Sale	21.64	774,142	16,752,433	34,749,305	Dec 15 09:34 PM
Ramaswamy Vivek	10% Owner	Dec 15 '25	Sale	22.05	353,745	7,800,077	34,132,463	Dec 15 09:34 PM
Gline Matthew	Officer	Dec 15 '25	Proposed Sale	21.68	1,740,000	37,723,200		Dec 15 04:36 PM
Roivant Sciences Ltd.	Director	Dec 12 '25	Buy	21.00	16,666,666	349,999,986	113,317,007	Dec 12 05:17 PM
Venker Eric	President & Immunovant CEO	Dec 09 '25	Option Exercise	3.85	200,000	770,000	1,697,908	Dec 11 09:00 PM
Venker Eric	President & Immunovant CEO	Dec 09 '25	Sale	20.85	200,000	4,170,000	1,497,908	Dec 11 09:00 PM
Venker Eric	Officer	Dec 09 '25	Proposed Sale	20.85	200,000	4,169,131		Dec 09 04:49 PM
MANCHESTER KEITH S	Director	Nov 19 '25	Sale	20.23	1,300,000	26,304,500	18,047,727	Nov 21 08:24 PM
Gold Daniel Allen	Director	Nov 19 '25	Sale	20.23	1,300,000	26,304,500	18,047,727	Nov 21 08:22 PM
QVT Financial LP	Director by Deputization	Nov 19 '25	Sale	20.23	1,300,000	26,304,500	18,047,727	Nov 21 08:15 PM
Ramaswamy Vivek	10% Owner	Nov 14 '25	Sale	20.33	1,027,670	20,892,531	34,193,406	Nov 17 05:52 PM
Ramaswamy Vivek	10% Owner	Nov 17 '25	Sale	20.51	539,650	11,068,222	33,653,756	Nov 17 05:52 PM
Ramaswamy Vivek	10% Owner	Nov 13 '25	Sale	20.81	287,283	5,978,359	35,221,076	Nov 17 05:52 PM
Venker Eric	President & Immunovant CEO	Nov 07 '25	Option Exercise	3.85	200,000	770,000	1,704,959	Nov 07 09:00 PM
Venker Eric	President & Immunovant CEO	Nov 07 '25	Sale	20.22	200,000	4,044,000	1,504,959	Nov 07 09:00 PM
Venker Eric	Officer	Nov 07 '25	Proposed Sale	20.22	200,000	4,043,960		Nov 07 03:15 PM
Venker Eric	President & Immunovant CEO	Oct 15 '25	Option Exercise	15.85	414,683	6,572,726	1,919,642	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 16 '25	Option Exercise	15.85	318,282	5,044,770	1,823,241	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 17 '25	Option Exercise	15.85	118,418	1,876,925	1,623,377	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 15 '25	Sale	16.93	414,683	7,020,583	1,504,959	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 16 '25	Sale	17.05	318,282	5,426,708	1,504,959	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 17 '25	Sale	17.06	118,418	2,020,211	1,504,959	Oct 17 09:00 PM
Venker Eric	Officer	Oct 17 '25	Proposed Sale	17.06	118,418	2,020,171		Oct 17 04:01 PM
Venker Eric	Officer	Oct 16 '25	Proposed Sale	17.05	318,282	5,425,645		Oct 16 04:37 PM
Venker Eric	Officer	Oct 15 '25	Proposed Sale	16.93	414,683	7,021,429		Oct 15 04:23 PM
Venker Eric	President & Immunovant CEO	Oct 09 '25	Option Exercise	15.85	104,940	1,663,299	1,609,899	Oct 14 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 13 '25	Option Exercise	15.85	20,727	328,523	1,525,686	Oct 14 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 09 '25	Sale	16.30	104,940	1,710,522	1,504,959	Oct 14 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 13 '25	Sale	16.25	20,727	336,814	1,504,959	Oct 14 09:00 PM
Venker Eric	Officer	Oct 13 '25	Proposed Sale	16.25	20,727	336,877		Oct 14 08:51 AM
Venker Eric	Officer	Oct 09 '25	Proposed Sale	16.30	104,940	1,710,040		Oct 09 04:12 PM
Venker Eric	President & Immunovant CEO	Oct 07 '25	Option Exercise	7.21	355,161	2,559,093	1,860,120	Oct 08 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 06 '25	Option Exercise	13.29	171,396	2,277,775	1,676,355	Oct 08 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 08 '25	Option Exercise	8.07	138,602	1,119,164	1,643,561	Oct 08 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 07 '25	Sale	16.15	355,161	5,735,850	1,504,959	Oct 08 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 06 '25	Sale	16.34	171,396	2,800,611	1,504,959	Oct 08 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 08 '25	Sale	16.20	138,602	2,245,352	1,504,959	Oct 08 09:00 PM
Venker Eric	Officer	Oct 08 '25	Proposed Sale	16.20	138,602	2,244,797		Oct 08 04:15 PM
Venker Eric	Officer	Oct 07 '25	Proposed Sale	16.15	355,161	5,734,289		Oct 07 04:34 PM
Venker Eric	Officer	Oct 06 '25	Proposed Sale	16.34	171,396	2,800,365		Oct 06 04:46 PM
Venker Eric	President & Immunovant CEO	Sep 19 '25	Option Exercise	3.85	1,000,000	3,850,000	2,653,585	Sep 23 09:00 PM
Venker Eric	President & Immunovant CEO	Sep 22 '25	Option Exercise	3.85	562,374	2,165,140	2,532,141	Sep 23 09:00 PM
Venker Eric	President & Immunovant CEO	Sep 19 '25	Sale	14.95	683,818	10,223,079	1,969,767	Sep 23 09:00 PM
Venker Eric	President & Immunovant CEO	Sep 23 '25	Sale	14.83	611,000	9,061,130	1,504,959	Sep 23 09:00 PM
Venker Eric	President & Immunovant CEO	Sep 22 '25	Sale	14.99	416,182	6,240,568	2,115,959	Sep 23 09:00 PM
Venker Eric	Officer	Sep 23 '25	Proposed Sale	14.94	611,079	9,129,520		Sep 23 09:45 AM
ERIC VENKER	Officer	Sep 22 '25	Proposed Sale	14.99	316,182	4,741,054		Sep 22 04:20 PM
Venker Eric	Officer	Sep 22 '25	Proposed Sale	15.01	100,000	1,501,339		Sep 22 04:07 PM
ERIC VENKER	Officer	Sep 19 '25	Proposed Sale	14.95	683,818	10,220,412		Sep 19 04:32 PM
Gline Matthew	CEO	Sep 18 '25	Buy	15.07	3,315	49,957	17,287,081	Sep 18 07:28 PM
Ramaswamy Vivek	10% Owner	Sep 03 '25	Sale	12.50	1,195,000	14,937,500	36,089,108	Sep 05 05:01 PM
Ramaswamy Vivek	10% Owner	Sep 05 '25	Sale	12.96	385,816	5,000,175	35,508,359	Sep 05 05:01 PM
Ramaswamy Vivek	10% Owner	Sep 04 '25	Sale	12.92	194,933	2,518,534	35,894,175	Sep 05 05:01 PM
Venker Eric	President & Immunovant CEO	Aug 20 '25	Option Exercise	3.85	100,000	385,000	1,753,585	Aug 22 09:00 PM
Venker Eric	President & Immunovant CEO	Aug 20 '25	Sale	11.72	100,000	1,172,000	1,653,585	Aug 22 09:00 PM
Venker Eric	Officer	Aug 20 '25	Proposed Sale	11.72	100,000	1,172,120		Aug 20 04:30 PM
Venker Eric	President & Immunovant CEO	Jul 21 '25	Option Exercise	3.85	100,000	385,000	1,562,223	Jul 23 09:00 PM
Venker Eric	President & Immunovant CEO	Jul 21 '25	Sale	11.52	100,000	1,152,000	1,462,223	Jul 23 09:00 PM
Venker Eric	Officer	Jul 21 '25	Proposed Sale	11.52	100,000	1,151,942		Jul 21 04:34 PM
Venker Eric	President & COO	Jun 20 '25	Option Exercise	3.85	100,000	385,000	1,562,223	Jun 24 09:01 PM
Venker Eric	President & COO	Jun 20 '25	Sale	11.45	100,000	1,145,000	1,462,223	Jun 24 09:01 PM
Ramaswamy Vivek	10% Owner	Jun 20 '25	Sale	11.46	577,007	6,612,500	37,284,108	Jun 23 11:35 AM

Open in Screener

ABUS

Arbutus Biopharma Corp

Feb 12 • 04:00PM ET

4.01

-0.15 -3.61 %

Healthcare • Biotechnology • USA • NASD

ABUS Arbutus Biopharma Corp daily Stock Chart

Peers: GILD REGN ALNY MRNA VRTX EXEL NBIX BMRN SRPT BLUE

| Held by: VTI IWM XBI VXF IWO IBB VTWO SCHA KOMP VHT

Index	RUT	P/E	-	EPS (ttm)	-0.22	Insider Own	21.88%	Shs Outstand	191.95M	Perf Week	9.26%
Market Cap	771.22M	Forward P/E	-	EPS next Y	-0.16	Insider Trans	0.00%	Shs Float	150.24M	Perf Month	-15.40%
Enterprise Value	682.13M	PEG	-	EPS next Q	-0.04	Inst Own	62.45%	Short Float	9.02%	Perf Quarter	-14.86%
Income	-42.28M	P/S	52.79	EPS this Y	50.59%	Inst Trans	-0.23%	Short Ratio	8.96	Perf Half Y	18.99%
Sales	14.61M	P/B	9.94	EPS next Y	14.78%	ROA	-35.50%	Short Interest	13.56M	Perf YTD	-16.63%
Book/sh	0.40	P/C	8.23	EPS next 5Y	-	ROE	-45.88%	52W High	5.10 -21.37%	Perf Year	21.15%
Cash/sh	0.49	P/FCF	-	EPS past 3/5Y	23.21% 33.46%	ROIC	-51.89%	52W Low	2.70 48.24%	Perf 3Y	49.07%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-17.50% 0.53%	Gross Margin	95.31%	Volatility	7.34% 7.52%	Perf 5Y	-7.39%
Dividend TTM	-	EV/Sales	46.69	EPS Y/Y TTM	47.93%	Oper. Margin	-214.67%	ATR (14)	0.30	Perf 10Y	33.67%
Dividend Ex-Date	-	Quick Ratio	18.80	Sales Y/Y TTM	116.64%	Profit Margin	-289.45%	RSI (14)	44.18	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	18.80	EPS Q/Q	61.27%	SMA20	-2.47%	Beta	0.72	Target Price	6.00
Payout	-	Debt/Eq	0.06	Sales Q/Q	-60.49%	SMA50	-9.41%	Rel Volume	1.36	Prev Close	4.16
Employees	44	LT Debt/Eq	0.05	Earnings	Nov 13 BMO	SMA200	1.25%	Avg Volume	1.51M	Price	4.01
IPO	Jul 23, 2007	Option/Short	Yes / Yes	EPS/Sales Surpr.	-33.33% -58.24%	Trades		Volume	2,033,485	Change	-3.61%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-02-22	Upgrade	Jefferies	Hold → Buy	$5
Feb-25-21	Initiated	Jefferies	Hold	$5
Dec-17-20	Initiated	H.C. Wainwright	Buy	$10
Jul-27-20	Resumed	JMP Securities	Mkt Outperform	$10 → $8
Jul-24-20	Downgrade	Robert W. Baird	Outperform → Neutral
May-19-20	Upgrade	Wedbush	Neutral → Outperform
Mar-06-20	Upgrade	Chardan Capital Markets	Neutral → Buy	$5
Feb-20-20	Initiated	Robert W. Baird	Outperform	$8
Feb-05-20	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform	$10
Oct-07-19	Reiterated	B. Riley FBR	Buy	$7 → $3
Oct-04-19	Downgrade	Chardan Capital Markets	Buy → Neutral
Oct-16-18	Upgrade	B. Riley FBR	Neutral → Buy	$11.50 → $9
Oct-15-18	Upgrade	Wedbush	Underperform → Neutral	$5
Oct-12-18	Reiterated	Chardan Capital Markets	Buy	$12 → $6.50
Jul-06-18	Downgrade	B. Riley FBR, Inc.	Buy → Neutral	$9 → $9
Mar-19-18	Resumed	Chardan Capital Markets	Buy	$8.25
Mar-19-18	Downgrade	Wedbush	Outperform → Neutral	$9 → $6
Jan-05-18	Initiated	B. Riley FBR, Inc.	Buy	$10
Apr-04-17	Upgrade	Chardan Capital Markets	Neutral → Buy	$3 → $6
Feb-01-17	Reiterated	Wedbush	Outperform	$13 → $10

Show Previous Ratings

Feb-06-26 12:33PM	Moderna faces $5 billion mRNA patent lawsuit after 'Star Trek' ruling (TheStreet)
Jan-12-26 12:00PM	Arbutus (ABUS) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-13-25 07:30AM	Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) -5.79%
Oct-07-25 08:00AM	Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting 2025 (GlobeNewswire)
Oct-03-25 09:40AM	Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year? (Zacks)
09:40AM	Loading…
Sep-17-25 09:40AM	Is Novartis (NVS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Sep-01-25 09:40AM	Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-14-25 09:40AM	Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-06-25 08:40AM	Arbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates (Zacks)
07:45AM	Arbutus: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-25-25 07:30AM	Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus (GlobeNewswire)
May-14-25 08:45AM	Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:39AM	Arbutus: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
05:15PM	Loading…
May-13-25 05:15PM	Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
09:40AM	Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year? (Zacks)
May-07-25 02:01AM	Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025 (GlobeNewswire)
Apr-25-25 09:40AM	Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Apr-24-25 10:02AM	Will Arbutus Biopharma (ABUS) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-23-25 02:01AM	Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025 (GlobeNewswire)
Mar-31-25 12:00PM	All You Need to Know About Arbutus (ABUS) Rating Upgrade to Buy (Zacks)
09:40AM	Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year? (Zacks)
Mar-28-25 09:48AM	Arbutus Biopharma: A Wing And A Prayer (Seeking Alpha) +7.03%
09:00AM	RNA Biotechs: Current State And Outlook (Seeking Alpha)
07:01AM	Novo gains Lexicon obesity drug; CRISPR COO to step down (BioPharma Dive)
Mar-27-25 08:45AM	Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-26-25 03:45PM	As Vaccine Skepticism Mounts, Modernas Business Grows More Precarious (Barrons.com)
Mar-03-25 09:15AM	Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna (GlobeNewswire)
07:00AM	Loading…
Feb-25-25 07:00AM	Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO (GlobeNewswire)
Feb-12-25 09:24AM	Is Arbutus Biopharma Corp. (ABUS) the Best Nasdaq Stock Under $5 to Buy? (Insider Monkey)
Jan-16-25 11:22AM	Jim Cramer on Arbutus Biopharma Corporation (ABUS): It Loses Money (Insider Monkey)
Jan-13-25 07:30AM	Arbutus Provides 2025 Corporate and Financial Update (GlobeNewswire)
Dec-06-24 08:20AM	Heres Why Arbutus (ABUS) Surged in Q3 (Insider Monkey)
Dec-03-24 08:00AM	Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors (Business Wire)
Nov-26-24 07:30AM	Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat (GlobeNewswire)
Nov-15-24 11:02AM	Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon (GlobeNewswire)
11:01AM	Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B (GlobeNewswire)
Nov-14-24 07:30AM	Arbutus to Present at Jefferies London Healthcare Conference (GlobeNewswire)
Nov-07-24 02:12AM	Arbutus Biopharma Corp (ABUS) Q3 2024 Earnings Call Highlights: Promising Clinical Trials and ... (GuruFocus.com)
02:07AM	Q3 2024 Arbutus Biopharma Corp Earnings Call (Thomson Reuters StreetEvents)
Nov-06-24 08:45AM	Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:40AM	Arbutus: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-23-24 07:30AM	Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update (GlobeNewswire)
Oct-15-24 08:16AM	Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting 2024 (GlobeNewswire) +6.48%
Oct-01-24 07:30AM	Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference (GlobeNewswire)
Sep-25-24 09:40AM	Has Arbutus Biopharma (ABUS) Outpaced Other Medical Stocks This Year? (Zacks)
Sep-03-24 07:30AM	Arbutus to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-22-24 09:40AM	Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-06-24 09:40AM	Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year? (Zacks)
Aug-02-24 01:51AM	Q2 2024 Arbutus Biopharma Corp Earnings Call (Thomson Reuters StreetEvents)
Aug-01-24 08:40AM	Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:41AM	Arbutus: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-18-24 07:30AM	Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update (GlobeNewswire)
Jun-06-24 11:15AM	Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels (GlobeNewswire) -7.99%
11:15AM	Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B (GlobeNewswire)
Jun-05-24 02:30AM	Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure (GlobeNewswire) +8.68%
May-29-24 07:30AM	Arbutus to Participate in Jefferies Global Healthcare Conference (GlobeNewswire)
May-22-24 02:00AM	Arbutus to Present Imdusiran Data at EASL Congress 2024 (GlobeNewswire) +6.23%
May-17-24 12:03PM	Update: Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program (MT Newswires)
10:40AM	Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program (MT Newswires)
09:00AM	Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value (Business Wire)
May-07-24 07:30AM	Arbutus to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
May-03-24 11:19AM	Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:24AM	Arbutus Biopharma Corp (ABUS) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-02-24 12:55PM	ABUS Stock Earnings: Arbutus Biopharma Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:58AM	Arbutus Biopharma Corp Reports Q1 2024 Earnings: A Detailed Financial Review (GuruFocus.com)
08:45AM	Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:44AM	Arbutus: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
07:25AM	Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024 (GlobeNewswire)
Apr-30-24 09:40AM	Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year? (Zacks)
Apr-18-24 07:30AM	Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update (GlobeNewswire)
Apr-04-24 08:30AM	Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna (GlobeNewswire)
Mar-08-24 07:30AM	Arbutus to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Mar-01-24 08:17AM	Arbutus Biopharma Corporation (NASDAQ:ABUS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-29-24 11:14PM	Q4 2023 Arbutus Biopharma Corp Earnings Call (Thomson Reuters StreetEvents)
08:40AM	Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:52AM	Arbutus Biopharma Corp (ABUS) Reports Year-End Financial Results and Progress in Clinical Trials (GuruFocus.com)
07:30AM	Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-15-24 07:30AM	Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update (GlobeNewswire)
Jan-08-24 07:30AM	Arbutus Announces 2024 Corporate Objectives and Provides Financial Update (GlobeNewswire)
Nov-09-23 04:24PM	Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD (GlobeNewswire)
04:01PM	Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting (GlobeNewswire)
09:12AM	Arbutus Biopharma Corporation (NASDAQ:ABUS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 07:30AM	Arbutus to Present at Jefferies London Healthcare Conference (GlobeNewswire)
01:16AM	Q3 2023 Arbutus Biopharma Corp Earnings Call (Thomson Reuters StreetEvents)
Nov-07-23 08:05AM	Arbutus Biopharma Corp (ABUS) Reports Q3 2023 Financial Results (GuruFocus.com)
07:40AM	Arbutus: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
07:15AM	Arbutus Announces CEO, William Collier, to Retire December 31, 2023 (GlobeNewswire)
Oct-30-23 09:32AM	12 Best Micro Cap Stocks To Invest In (Insider Monkey)
Oct-24-23 07:30AM	Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update (GlobeNewswire)
Oct-18-23 07:30AM	Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference (GlobeNewswire) -5.82%
Oct-11-23 08:05AM	Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting 2023 (GlobeNewswire)
Sep-12-23 10:56AM	Arbutus BioPharma narrows research focus to extend cash runway (American City Business Journals) -7.73%
08:58AM	Arbutus (ABUS) to Focus on Hepatitis B Candidates, Stock Up (Zacks)

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	SEC Form 4
McElhaugh Michael J.	Director	Apr 21 '25	Proposed Sale	3.26	246,886	804,850	Apr 21 02:11 PM
McElhaugh Michael J.	Director	Apr 15 '25	Proposed Sale	3.20	53,114	170,098	Apr 15 04:27 PM
Sofia Michael J.	Officer	Mar 31 '25	Proposed Sale	3.50	250,000	875,000	Mar 31 09:42 AM
Sofia Michael J.	Officer	Mar 24 '25	Proposed Sale	3.28	250,000	820,000	Mar 24 09:19 AM
Sofia Michael J.	Officer	Mar 19 '25	Proposed Sale	3.20	150,000	480,000	Mar 19 09:34 AM
Sofia Michael J.	Officer	Mar 13 '25	Proposed Sale	3.38	100,000	338,000	Mar 13 03:55 PM
Sofia Michael J.	Member of immediate family of	Mar 07 '25	Proposed Sale	3.29	167,162	549,963	Mar 07 02:59 PM

ROIV

Roivant Sciences Ltd

ABUS

Arbutus Biopharma Corp

Upgrade your FINVIZ experience